Browsing by Author "Alotaibi, Hani"

Now showing 1 - 3 of 3

Unknown
The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity
(Public Library of Science, 2010) Mumcuoğlu, Mine; Bağışlar, Sevgi; Yüzügüllü, Haluk; Alotaibi, Hani; Şentürk, Şerif; Telkoparan, Pelin; Gür-Dedeoğlu, Bala; Cingöz, Burcu; Bozkurt, B.; Tazebay, Uygar H.; Yuluğ, Işık G.; Akçalı, Kamil Can; Öztürk, Mehmet
Background Breast cancer is a remarkably heterogeneous disease. Luminal, basal-like, "normal-like", and ERBB2+ subgroups were identified and were shown to have different prognoses. The mechanisms underlying this heterogeneity are poorly understood. In our study, we explored the role of cellular differentiation and senescence as a potential cause of heterogeneity. Methodology/Principal Findings A panel of breast cancer cell lines, isogenic clones, and breast tumors were used. Based on their ability to generate senescent progeny under low-density clonogenic conditions, we classified breast cancer cell lines as senescent cell progenitor (SCP) and immortal cell progenitor (ICP) subtypes. All SCP cell lines expressed estrogen receptor (ER). Loss of ER expression combined with the accumulation of p21Cip1 correlated with senescence in these cell lines. p21Cip1 knockdown, estrogen-mediated ER activation or ectopic ER overexpression protected cells against senescence. In contrast, tamoxifen triggered a robust senescence response. As ER expression has been linked to luminal differentiation, we compared the differentiation status of SCP and ICP cell lines using stem/progenitor, luminal, and myoepithelial markers. The SCP cells produced CD24+ or ER+ luminal-like and ASMA+ myoepithelial-like progeny, in addition to CD44+ stem/progenitor-like cells. In contrast, ICP cell lines acted as differentiation-defective stem/progenitor cells. Some ICP cell lines generated only CD44+/CD24-/ER-/ASMA- progenitor/stem-like cells, and others also produced CD24+/ER- luminal-like, but not ASMA+ myoepithelial-like cells. Furthermore, gene expression profiles clustered SCP cell lines with luminal A and "normal-like" tumors, and ICP cell lines with luminal B and basal-like tumors. The ICP cells displayed higher tumorigenicity in immunodeficient mice. Conclusions/Significance Luminal A and "normal-like" breast cancer cell lines were able to generate luminal-like and myoepithelial-like progeny undergoing senescence arrest. In contrast, luminal B/basal-like cell lines acted as stem/progenitor cells with defective differentiation capacities. Our findings suggest that the malignancy of breast tumors is directly correlated with stem/progenitor phenotypes and poor differentiation potential.
Unknown
Alteration in the subcellular location of the inhibitor of growth protein p33(ING1b) in estrogen receptor alpha positive breast carcinoma cells
(Scientific and Technical Research Council of Turkey, 2017) Kunter, İ.; Kandemiş, E.; Alotaibi, Hani; Canda, T.; Bağrıyanık, E. E.
ING1 has regulatory roles in the expression of genes associated with proliferation, apoptosis, and senescence. p33(ING1b) is the most widely expressed isoform of the gene. Downregulation of its nuclear expression is involved in differentiation and pathogenesis in invasive breast carcinoma. Yet the mechanism(s) by which p33 nuclear targeting is regulated remains unknown. In this study, we analyzed human invasive breast carcinoma tissue samples by immunostaining with p33 and correlating p33 location with the presence of ERα. Our findings show the expression of p33 protein in ERα-positive tumor samples was in the nucleus alone, while the expression was mainly in the cytoplasm in ERα-negative tumor samples. Examination of the localization of p33 in the nucleus and/or cytoplasm in several different cell lines demonstrated 17β-estradiol (E2) treatment causes dramatic compartmental shift in p33 protein from the cytoplasm to the nucleus in ERα-positive MDA-66 cells. No significant differences in ERα-negative MDA-MB-231 cells in the same conditions were observed. We show for the first time nuclear localization of p33 is regulated by estradiol induction in ERα-positive breast cancer cells. These results suggest compartmental shift in p33 by ER signaling may be an important molecular event in the differentiation and pathogenesis of invasive breast cancer. © TÜBİTAK.
Unknown
Identification of novel genetic elements controlling transcriptional regulation of the human Na(formula)/I(formula) symporter (NIS) gene
(2006) Alotaibi, Hani
The function of sodium iodide symporter (NIS) in mammary gland epithelial cells is essential for the accumulation of iodide in mother’s milk, which is the first source of iodide for the synthesis of thyroid hormones in the newborn. In addition to the lactating mammary gland, NIS expression has been also detected in breast tumors. Several hormones and ligands have been implicated in the functional expression of NIS in the mammary gland and breast cancer cell line models but the molecular determinants governing this expression are not yet identified. In this study we aimed to identify cis- and trans-acting elements regulating NIS expression in the breast cancer cell line MCF-7 in response to all-trans-retinoic acid (tRA), and to assess the possible role of 17-β-estradiol (E2) in regulating the expression of NIS. Using comparative bioinformatics, we have identified several regions that were conserved in human, mouse and rat in the sequences flanking and including the NIS gene. By using luciferase reporter assays, we have established that conserved clusters 3 and 4 respond to tRA in MCF-7. We have also shown that putative retinoic acid response elements controlling tRA-induced NIS expression in MCF-7 are located in the first intron of this gene. This tRA-responsive NIS expression was also correlated with the estrogen receptor status of mammary gland cell lines and we investigated roles of ERα in the regulation of NIS expression. We showed that the suppression of endogenous ERα by RNA interference resulted in down-regulation of both basal and tRA-induced NIS expression in MCF-7, furthermore, we have also shown that (E2) is capable of up-regulating NIS expression in MCF-7. In the ERα negative cell line MDA-MB-231, re-introduction of ERα resulted in NIS expression in a ligand independent manner. The role of ERα in the regulation of NIS expression was supported by the identification of an estrogen response element (ERE) in the promoter of NIS, this ERE was conserved in human, mouse and rat. We have also showed that this ERE could respond to E2 stimulation, and that ERα occupies the NIS promoter by binding to this novel element in vivo. These results indicate that E2 and ERα contribute to the regulation of NIS in the breast cancer cell line MCF-7.